Merck's lung cancer treatment receives FDA approval

Tuesday, 18. June 2019 13:10

Pharmaceutical giant Merck & Co. announced on Tuesday that its small cell lung cancer treatment Keytruda received an approval from the United States Food and Drug Administration (FDA). The medicine is intended for patients with metastatic lung cancer, with the condition progressing on or after chemotherapy or at least one other line of treatment.

"KEYTRUDA is already an established treatment option for non-small cell lung cancer, and today’s approval in small cell lung cancer demonstrates our commitment to bringing forward new treatment options for patients with advanced, difficult-to-treat cancers," Merck's vice president for oncology clinical research Dr. Jonathan Cheng commented.

Following the announcement, Merck stock jumped 0.72% in Tuesday's premarket trading on the New York Stock Exchange.

Related Links: Merck & Co. Inc.
Breaking the News / SS